Zogenix Appoints New Chief Commercial Officer
Scott has over 30 years of pharmaceutical industry experience in a variety of sales and marketing leadership positions including responsibility for early stage programs and an impressive list of successfully commercialized products, with extensive experience in pain. In his most recent role at Pfizer, Scott had global commercial leadership responsibility for Pfizer's primary care pain franchise including products such as Lyrica, Celebrex and Embeda, as well as for all pain pipeline products, and was the lead interface for Pfizer's Pain discovery research unit. Also while at Pfizer, Scott was heavily involved in the establishment and potential business expansion of Pfizer's new Integrated Health Business Unit. Prior to Pfizer, Scott was senior vice president for commercial operations at
"Because of his extensive experience in building commercial organizations, successful brands and companies of all sizes, Scott is the ideal choice to join our
For additional information, please visit www.zogenix.com.
SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of